Outcomes of Gillian Barrie Syn

NCT07208370 | Not Yet Recruiting

• 1 other identifier: Outcomes of Gillian barrie Syn
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study analyze clinical and biological factors influencing disease course and outcome. Some research identified factors like disease severity, sensory symptoms, and autonomic instability as indicators of poor outcome. Ongoing research aims to develop accurate predictive models for improved treatment and care.

Conditions

Outcome of Gillian Barrie

Outcome Measures

Primary Outcomes (1)

• Proportion of Pediatric Patients with Guillain-Barré Syndrome Achieving Full Recovery within 3 Months

  Proportion of pediatric patients with Guillain-Barré Syndrome achieving full recovery, as assessed by the Hughes Functional Grading Scale, within 3 months of diagnosis.

  first 3 months after diagnosis

Study Arms (1)

GBS Group

EXPERIMENTAL

Other: clinical assessment

Interventions

clinical assessment OTHER

standraized clinical evaluation to assess disease sevirity and progration

GBS Group

Eligibility Criteria

• Age: 1 Month - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• All Pediatric patients (1 month to 18 years old) admitted with acute flaccid ascending paralysis and diagnosed as GBS.
• Consent obtained from parents or legal guardians for participation and follow-up.

You may not qualify if:

• Children with pre-existing neuromuscular disorders. Patients with incomplete medical records or those lost to follow-up. Cases diagnosed as chronic inflammatory demyelinating polyneuropathy (CIDP).

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Assuit University Hospital

Asyut, Egypt

Location

Related Publications (5)

• Kalita J, Kumar M, Misra UK. Prospective comparison of acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy in 140 children with Guillain-Barre syndrome in India. Muscle Nerve. 2018 May;57(5):761-765. doi: 10.1002/mus.25992. Epub 2017 Nov 7.

  PMID: 29053890 BACKGROUND

• Koul RL, Alfutaisi A. Prospective study of children with Guillain-Barre syndrome. Indian J Pediatr. 2008 Aug;75(8):787-90. doi: 10.1007/s12098-008-0099-1. Epub 2008 Jun 25.

  PMID: 18581067 BACKGROUND

• Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):711-8. doi: 10.1136/jnnp-2011-301882. Epub 2012 May 7.

  PMID: 22566597 BACKGROUND

• Korinthenberg R. Acute polyradiculoneuritis: Guillain-Barre syndrome. Handb Clin Neurol. 2013;112:1157-62. doi: 10.1016/B978-0-444-52910-7.00036-2.

  PMID: 23622324 BACKGROUND

• Shahrizaila N, Yuki N. Antiganglioside antibodies in Guillain-Barre syndrome and its related conditions. Expert Rev Neurother. 2011 Sep;11(9):1305-13. doi: 10.1586/ern.11.114.

  PMID: 21864076 BACKGROUND

Central Study Contacts

nourhan maher fawzy farah, principal investigator

CONTACT

+201204992604; Norhan.17289711@med.aun.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: principal investigator

Study Record Dates

• First Submitted: September 15, 2025
• First Posted: October 6, 2025
• Study Start: October 1, 2025
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: October 6, 2025

Record last verified: 2025-09

Locations

EG (1)